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More people die annually fromcardiovascular diseases than fromany other cause. In particular, patientswho suffer frommyocardial
infarction may be affected by ongoing adverse remodeling processes of the heart that may ultimately lead to heart failure. The
introduction of stem and progenitor cell-based applications has raised substantial hope for reversing these processes and inducing
cardiac regeneration. However, current stem cell therapies using single-cell suspensions have failed to demonstrate long-lasting
efficacy due to the overall low retention rate after cell delivery to the myocardium. To overcome this obstacle, the concept of 3D
cell culture techniques has been proposed to enhance therapeutic efficacy and cell engraftment based on the simulation of an in
vivo-like microenvironment. Of great interest is the use of so-called microtissues or spheroids, which have evolved from their
traditional role as in vitro models to their novel role as therapeutic agents. This review will provide an overview of the therapeutic
potential ofmicrotissues by addressing primarily cardiovascular regeneration. It will accentuate their advantages compared to other
regenerative approaches and summarize the methods for generating clinically applicable microtissues. In addition, this review
will illustrate the unique properties of the microenvironment within microtissues that makes them a promising next-generation
therapeutic approach.
1. Introduction
Stimulated by the aging population, intense effort has been
invested in the development of new strategies to address
medical challenges [1]. Although the human body has life-
long regenerative potential by recruiting progenitor cells to
replace lost cells through proliferation and differentiation, the
endogenous regenerative capacity is limited and often insuf-
ficient after extensive tissue injury. Therefore, conventional
treatments and interventions are primarily symptomatic and
are usually not capable of curing the disease [2]. To achieve
full recovery, it is critical to address the problem at its source
by removing the cause and not merely postponing the con-
sequences of tissue degeneration by applying symptomatic
therapies. In this setting, regenerative medicine using stem
and progenitor cells has emerged as a new and promising
field [3]. The main objective is to replace damaged cells
and, therefore, to restore the physiological structure and
functionality of the diseased organs [4].With stem cells as key
players, the domain of regenerative medicine is continuously
expanding from single-cell injections to the engineering of
larger tissue implants that also include extracellular matrix
(ECM) embedding of an entire arrangement of cells [5].
Cardiovascular diseases have been of particular interest
for innovative (translational) therapy options because they
could benefit significantly from a regenerative approach. The
heart is known to have a limited capacity for self-regeneration
[6, 7]. Current therapies after myocardial infarction (MI)
mainly involve pharmaceutical approaches and surgical
or percutaneous revascularization. Unfortunately, ischemic
heart disease is progressive, and the loss of cardiomyocytes
provokes further remodeling processes that negatively affect
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the course of the disease [8, 9]. Therefore, contemporary
options are only palliative and delay the fatality of the
pathologies, which could ultimately only be averted with
heart transplantation. However, an organ shortage and the
necessity for lifelong immunosuppressive therapy signifi-
cantly limit the application of this therapy option to a subset
of patients [10, 11].
Over the past decade, several cell types have been exam-
ined for their capacity to repair and regenerate the heart. Bone
marrow, and particularly its collection of subpopulations,
including mesenchymal stem cells (MSCs) and endothelial
progenitor cells (EPCs), has been evaluated intensively. In
addition, other attractive sources, such as adipose tissue
or the umbilical cord, could harbor a reservoir of suitable
stem cells for cardiac repair. Furthermore, the detection
of inherent progenitor cells in the human heart pioneered
the development of next-generation approaches involving
cardiac-derived stem cells from the heart itself as well as stem
cells guided toward differentiation along the cardiac lineage
ex vivo [5, 8, 12–14]. Many cell types have demonstrated
promising results in preclinical trials, and clinical pilot
studies have proven that these methods are feasible and safe,
thereby raising hope for curing the human heart. However,
in regard to efficiency, the outcomes were disappointing,
and the minimal benefit showed that the strategies needed
to be revised [5, 10, 15]. Several critical but controversial
factors are responsible for the lack of success. Among the
most fundamental points of debate are the optimal cell type,
the delivery method, and the timing. A main focus must
also be on the cell format [3, 10, 11]. Cells can be injected
intracoronary or directly into the myocardium. Regardless
of the route of delivery, one essential obstacle appears to be
engraftment [5, 15, 16]. To exploit their full potential, cells
need to be retained at the site of injury, and their long-
term survival is a prerequisite to enable them to fully operate
[10]. The acute retention rates that were observed did not
exceed 10% [17]. Therefore, the cell format appears to play a
pivotal role in impeding the highwashout phenomenonof the
current standard approaches [18]. Consequently, the strategy
for the perfect implant has increasingly shifted to graft cells in
a three-dimensional (3D) design, which more closely mimics
living tissue. Compared to single-cell suspensions, stem cells
can also be transplanted as complex tissue constructs to
improve retention [5, 19]. However, it remains very chal-
lenging to design larger 3D cell constructs and, importantly,
to maintain their viability. In addition, instead of simple,
catheter-based injection, they often require more invasive
surgery to be delivered [3]. A potential solutionmay be small,
scaffold-free, 3D aggregates called microtissues. Microtissues
include between 500 and 10,000 cells and were initially used
as a model to elucidate tumor biology [5, 20]. However, as an
interesting concept for 3D cell culture, their application has
been extended to the area of regenerative medicine during
the last several years [21]. In the setting of cardiovascular
applications, microtissues may provide an optimal hybrid
format to implant stem cells into the injured heart. They
can be transplanted via transcatheter delivery because of
their scaffold-free concept [3]. Compared to dissociated cells,
their superior size and higher organized 3D state, along
with their inherent ECM, promote enhanced integration and
retention in the target tissue [17, 22]. In addition, they exhibit
versatile advantages over their single-cell counterparts that
are attributed to their 3D microenvironment, which also
better reflects the native situation in vivo [21]. Therefore,
microtissues have been repeatedly suggested to be themissing
link for enhancing the therapeutic potential of stem cell
therapy and bringing regenerative medicine a step closer to
clinical application in cardiovascular medicine [10].
This review article summarizes the different aspects of
microtissues in the context of cardiovascular regeneration.
In particular, it highlights the technical and functional
advantages of a scaffold-free 3D cell culture compared to
other cell-based regenerative approaches, including scaffold-
based and single-cell approaches. It emphasizes production
strategies formicrotissues for therapeutic purposes and notes
remaining challenges to providing a product that is imme-
diately available and accessible to a broad subset of patients.
Furthermore, this paper introduces the remarkable cues of
the in vivo-like microenvironment established in microtis-
sues, relates these cues to resulting therapeutic advantages
for cardiac regeneration, and refers to recent preclinical
studies that have addressed cardiovascular therapy with
microtissues. Finally, the potential ofmicrotissues as building
blocks for the generation of larger tissues is illustrated. As
shown in this review, merging state-of-the-art techniques
into an innovative, hybrid conceptmight result in a promising
approach for using microtissues for advanced and targeted
cardiac regeneration in the clinical arena.
2. Scaffold-Free versus Scaffold-Based
3D Tissue Culture
To understand the interest surrounding microtissues in the
regenerative field, it is important to compare them with
other tissue-engineering strategies, particularly the ones that
include the use of a scaffold.
2.1. 3D Culture. Cells in physiological tissue are part of a
versatile and dynamic network that can never be mimicked
by a monolayer cell culture [23]. To cultivate cells in a 3D
environment, there are different approaches available. Tissue
culture can be based on a scaffold that serves as a platform
for cell attachment and as a carrier for cell delivery [24], or
the cells themselves can serve as the platform to guide cell
aggregation tomicrotissues [25].There are several advantages
to providing cells in a 3D format:
(i) Microenvironment preserves physiological cell phe-
notype and gene expression profile.
(ii) Cell-cell interaction plays a crucial role in cellular
homeostasis.
(iii) ECM enhances integration and retention in target
tissue.
(iv) Hypoxic environment induces growth factor expres-
sion.
This format better mimics the physiological situation because
cells in living tissues are normally anchored to other cells
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or to the ECM [25]. These adhesions not only provide
mechanical anchor points but also influence cell behavior
through signaling properties of both components [26–28].
The comparison of cell cultures in 2D and 3D highlights the
improved cell functionality [29, 30] and regenerative capacity
[29, 31] created by 3D cultivation. In addition to the increased
physiological behavior, functionality, and vitality of cells in
3D tissues, the elevated secretion of ECM can enhance cell
viability and provide therapeutic advantages [29, 32].
2.2. Scaffold-Based Approaches. The two main concepts of
tissue engineering are the development of tissues with or
without scaffolds. Both have advantages and disadvantages,
and the strategy to engineer the ideal graft depends primarily
on the needs and features of the desired tissue (Table 1). Scaf-
folds can serve as an ECM mimetic, which can subsequently
home the cells. Because the ECM is a very complex and versa-
tile structure, it is difficult to mimic it optimally. Frequently,
biodegradable polymers have been used as scaffolds and can
be of either natural or synthetic origin [33]. Both scaffold
sources are made of external materials, which may cause
rejection and foreign body reactions as well as overgrowth
by fibroblasts [3]. While synthetic scaffolds may have a
lower risk of immunogenicity, there are concerns about the
biocompatibility of their degradation products [33]. Scaffolds
can be modified and activated in a nearly unlimited way by
modulating the surface chemically [34] or physically [35] or
by coupling biologically active molecules [36–38]. Possible
benefits of scaffold-based approaches are their strength and
mechanical support, their available capacity to adapt in size
to large areas of tissue damage, their guidance or preorganiza-
tion of cell growth and tissue shape, and the potential addition
of bioactive proteins andmolecules [33]. For complex tissues,
such as cardiac tissues, many aspects have to be considered
for the scaffold design because the native myocardial tissue
permanently switches between contraction and relaxation,
causing a high level of oxygen consumption [33]. The main
drawback of scaffold-based engineered tissues is the delivery
to the target organ or structure. Larger tissues may not
be applicable for a minimally invasive technique and may
require open surgical approaches, such as open-heart surgery,
when addressing cardiac tissues [3].
2.3. Scaffold-Free Approaches. In contrast to scaffold-based
strategies, tissue engineering without scaffolds is based on
the self-assembly of cells. Two established forms of scaffold-
free tissues are cell sheets and microtissues. Cell sheets can
be produced via 2D cultivation of cells on special surfaces that
allow the detachment of thewholemonolayer [39].Disadvan-
tages of these sheets are the difficulty in handling them due
to their thinness and the lack of catheter-based applicability
[33]. Microtissues can be produced by various methods that
promote the self-aggregation of cells to spheroids [26]. Their
handling appears to be easier, and they are injectable via
a transcatheter delivery technique [10], which is a signif-
icant advantage for clinical applications. Because of their
more native-like structure, they are capable of an elevated
secretion of ECM and paracrine factors [29]. Moreover,
compared to scaffold-based tissue-engineering approaches,
the use of microtissues circumvents obstacles, including
intense material investigation for the optimal scaffold, the
biocompatibility of the graft and its degradation products,
and scaffold degradation capacity [33].
For these reasons, microtissues have emerged as an
attractive alternative to scaffold-based strategies in the field
of tissue regeneration.
3. Production of Therapeutic Microtissues
While 3D, scaffold-free microtissues have several advantages
for regenerative therapies, their production has to be compli-
ant with clinical requirements, including simplicity, reduced
cost, product quality, standardization, and the possibility of
upscaling. This chapter will analyze the different existing
methods coming from the fields of both basic and clini-
cal research in terms of these requirements. Insights into
automation and biobanking will then be provided.
3.1. Methods for Microtissue Generation. Many approaches
are available for the production ofmicrotissues.They have the
common principle of culturing cells in an environmentwhere
cell-cell interactions prevail over cell-surface interactions
[40]. However, they all have advantages and disadvantages
regarding clinical requirements.
First, a simple and clinically compliant method of form-
ing microtissues without any external constraints occurs in
the cardiovascular field with cardiospheres. Cardiac biopsies
are enzymatically digested, yielding explants that are cultured
under specific conditions. Cells migrating from the explants
are harvested and spontaneously form niche-like spheroids
after seeding [41]. Remarkably, cardiosphere-derived cells
(CDCs) can be plated to form secondary cardiospheres, and
they possess significant cardiogenic potential [42]. CDCs
are currently considered to be among the most promising
cell types for cardiac regeneration, as shown by the suc-
cessful results of phase I clinical trial CADUCEUS [43]. We
suspect that the combination of CDCs/cardiospheres with
microtissues composed of other cell types, such as MSCs,
might even enhance this effect. However, formation of these
microtissues by other less-spontaneousmethods is necessary.
For example, the use of spinner flasks is a well-established
method for forming multicellular aggregates. Due to the
constantmixing of the cell suspension by a stirrer, the cells are
prevented fromattaching to thewall of the flask and aggregate
into microtissues [44]. Through variations in cell density
or stirring speed, the size and number of microtissues can
be tailored to specific needs. However, this method has the
disadvantage that cell behavior and viability can be affected
by constant shear stress [26, 45]. In turn, reduced cell viability
or functionality could be detrimental for implantation of
microtissues in vivo.
A possible solution to this problem is amethod developed
by NASA that involves the formation of spheroids using
microgravity. This approach is based on a special rotary
cell culture system that provides constant mixing of the cell
suspension with minimal shear forces through the constant
rotation of the outer wall of the bioreactor [46].
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In addition to product quality, other requirements for
microtissue generation for clinical applications are simplicity
and reduced cost. The liquid overlay technique has the
advantage that no special equipment is required because
either nonadhesive lab ware [47] or normal lab ware coated
with nonadhesive substances, such as agar [48] or agarose
[49, 50], can be used. Given that cells do not adhere to
the surface, they aggregate and form microtissues. However,
this occurs in a rather uncontrolled way that can lead to
high heterogeneity in the size of the microtissues [26].
Improved nonadhesion approaches ensure a more consistent
and homogenous size distribution. The standardization of
microtissue size, composition, and shape is of upmost impor-
tance in the clinical field. It can be achieved by seeding cells
in nonadhesive microstructures generated by micromolding.
Prominent inert materials that can be used to generate these
microstructures include agarose and polyacrylamide [51].
The use of external forces, such as centrifugation, ultra-
sound, and magnetic or electrical forces, can induce or
accelerate cell aggregation. By using low-speed centrifugation
of a cell suspension in a conical tube, cells form an aggregate
that may reach a relatively large diameter [52]. However,
the main disadvantages of this approach are again shear
forces and the difficulty of upscaling [21]. For the ultrasound-
guided generation of multicellular aggregates, an ultrasound
standing wave trap is utilized to direct cell aggregation
[53]. The 3D aggregation of cells can also be achieved
via positive dielectrophoresis [54]. Utilizing endocytosis of
liposomes containing magnetic nanoparticles allows cell
aggregation with magnetic forces [55]. However, while only
minor adverse effects on cell physiology have been reported
when applying external forces, these cannot be ruled out
completely. Another shortcoming of such methods is the
need for specialized equipment [26].
Microtissue production for regenerative therapy should
be standardized, reproducible, and, most importantly, cost-
effective to guarantee efficacy and, ultimately, translation into
clinics. The described approaches, which use external forces
(with the exception of low-speed centrifugation), including
constant mixing of the cell suspension, have the disadvantage
of needing special equipment, which increases production
costs and lowers the common availability of these platforms.
Because it uses common lab ware and reagents, the liquid
overlay technique is a cost-effective and easily reproducible
platform. However, the advanced and more standardized
micromolding technique requires specialized facilities and
therefore might not be easily transferrable to every lab [21,
26, 56].
The described methods have several shortcomings, such
as variable microtissue size, difficulty of upscaling, and a
harsh production environment with external forces.The pro-
duction of microtissues using the hanging drop method can
overcome some of these challenges because it is a very gentle
method for the production of well-defined microtissues with
a constant and reproducible cell number and size.
The hanging drop method is based on gravity-enforced
cell assembly, which is commonly achieved by pipetting small
drops of a cell suspension on the inner surface of a Petri
dish lid. By turning the lid upside down, a hanging drop
is formed and persists through surface tension. The cells
in the drop accumulate, driven by gravity, at the liquid/air
surface and form microtissues [57]. It has been shown
that this procedure for forming microtissues is applicable
for different cell sources including primary cells, such as
cardiomyocytes [58]; stem and progenitor cells, such as
embryonic ormesenchymal stem cells [16]; and immortalized
tumor cell lines, such as MCF-7 [57]. The production of
coculture microtissues with a defined composition is an
advantage of the hanging dropmethod. Furthermore, several
coculture and hybrid setups are feasible and comprise mixed
microtissues; microtissues coated with another cell type; or
so-called Janus microtissues, which are fused spheroids [40].
In summary, the hanging drop method using Petri dishes
is a cost-effective, gentle method that guarantees repro-
ducibility and does not require special equipment. However,
it is difficult to upscale and is not standardized. Tomeet these
requirements, more sophisticated hanging drop techniques
exist.
3.2. Automation. To facilitate standardized production of
microtissues, which is crucial for applications such as regen-
erative therapies or drug screening, an automated, high-
throughput approach is indispensable.
While the upscaling of the hanging drop procedure in a
Petri dish is inconvenient, several companies have recently
developed systems that are suitable for high-throughput
microtissue production [59, 60].Theyhave developed specific
plates for the modified production of hanging drops that
are based on multiwell plates with special wells that have
holes at the bottom for the formation of a hanging drop. The
great advantage of these novel systems is that they can be
combined with liquid handling systems for the automated,
standardized, high-throughput production of microtissues.
These automated approaches also overcome the challenge
of long-term cultivation, which is a main drawback of
the conventional hanging drop culture. The accessibility of
the hanging drop from the top enables media exchange,
which facilitates long-term cultivation of microtissues in
hanging drops [59]. These systems also simplify the addition
of reagents to individual microtissues in a hanging drop,
thereby substantially expanding the opportunity for potential
experimental settings and treatments [59].
Although automated hanging drop microtissue produc-
tion is rather expensive because of the need for special,
patented lab ware, its ability for large-scale production and
long-term cultivation of microtissues makes it a promising
and important tool for a wide range of biomedical appli-
cations, such as cytotoxicity studies and, more importantly,
tissue-engineering approaches for regenerative medicine.
3.3. Cryopreservation and Biobanking. For broad preclinical
and clinical applicability in the setting of regenerative or other
therapies, an off-the-shelf microtissue concept is desirable.
One important feature of an off-the-shelfmicrotissue product
is its instant availability for the aforementioned applications.
Therefore, key aspects, such as storability and, in particular,
cryopreservation, are of upmost importance [61].
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Ice formation during cryopreservation may be a crucial
and critical event because it can induce severe cell damage.
While freezing is commonly associated with ice formation,
ice can also be formed during thawing. Therefore, it is
important to identify optimal settings for freezing and thaw-
ing [62]. In addition to the common problems with the
cryopreservation of single cells, such as cryoinjury caused
by ice formation [62], there are additional obstacles for the
cryopreservation of 3D tissues.These include the microtissue
size-related impaired diffusion of substances like cytokines or
even gases, such as oxygen, to the inner part of microtissues
[63]. Regarding this limited mass transfer to the microtissue
core, the optimal incubation time of the cryoprotective agent
(CPA) needs to be determined based on microtissue size and
cell composition because a too-long incubation period may
harm the cells through CPA cytotoxicity [64]. Importantly,
the CPA should be distributed homogeneously within the
entire microtissue to protect the cells from intracellular ice
formation,which can lead to severe cell damage and cell death
[64, 65]. On the other hand, a too-intense incubationwith the
CPA may lead to enhanced dehydration of the cells, which
limits their capacity to recover after thawing [64].
During vitrification, liquids transform to a solid state
without ice formation. This can be achieved by rapid cooling
in combinationwithCPAswith a high osmolarity [64], result-
ing in the prevention of cryoinjury from ice formation [66].
However, the major drawbacks of this method are the use of
CPAs in a high concentration, which can lead to osmotically
induced cell damage [67], and the requirement for fast heat
transfer to achieve rapid cooling rates, whichmakes it difficult
to apply this method for larger-volume and high-throughput
biobanking [68]. By contrast, the slow-cooling approach is
accompanied by a reduced CPA cytotoxicity because lower
concentrations are needed [64]. However, a critical step for
slow cooling is determining the optimal cooling rate because
suboptimal cooling rates may cause either slow- or rapid-
cooling injury [69]. Moreover, every cell line has a specific
optimal cooling rate [62]. The ideal cooling rate of tissues
may also differ from their single-cell counterparts. It has been
shown that gap junctions between cells propagate intercel-
lular ice formation at a given temperature, which leads to
increased intracellular ice formation and finally to cryoinjury
[70]. With the help of special programmable freezers, it is
possible to upscale the sample volume to freeze, which would
be beneficial for cryobanking therapeutic microtissues. It has
also been shown that it can be advantageous to control the ice
nucleation by the addition of nucleants, such as cholesterol
[71]. For some cell sources, such as neural or embryonic
stem cells, freezing in aggregates results in higher numbers
of recovering cells than what can be achieved with single-cell
suspensions [72, 73]. This beneficial effect was attributed to
the cryoprotective effect of the surrounding ECM [73]. In this
context, it has been shown that 3D cell aggregates of neural
or embryonic stem cells can be cryopreserved with a large
quantity of cells recovering after thawing [72, 73].
Therefore, it seems promising that also other types of
microtissues can be safely cryopreserved by individually
adjusting all the parameters, such as CPA composition and
concentration, cooling method and rate, thawing rates, and
possible additives.
4. Microenvironment
While stem cell therapy is raising hope in the regenerative
field, the use of single-cell suspensions is expected to fail
at recapitulating the physiological 3D microenvironment of
cells. It is essential to consider cells in their entire context
because in nature, a cell is never without a surrounding that
has profound influence on its properties [23, 74].
Theuniquemicroenvironment that is generated inmicro-
tissues is crucial for the benefits of this culturing method
and can be considered to be the potential link to successful
regenerative therapies. The following chapter aims to reveal
the advantages of 3D spheroids relative to their microenvi-
ronment.
The biomimetic microenvironment that is sufficiently
established in microtissues bears a strong resemblance to
native tissues and is therefore capable of mimicking the real
conditions found in an organism [21]. For this reason, micro-
tissues are an excellent example of how cells themselves are
the best tissue engineers [75]. The cultured cells benefit from
the opportunity to interact with one another and to adhere
to their own secreted ECM. The intricacy of extensive cues
contributes to a more in vivo-like morphology, physiology,
and behavior of the cells and therefore improves basic cell
functions, including differentiation and proliferation [76–
78]. Microtissues produce a microenvironment that displays
the fundamental features of the environment produced in
natural tissues and its critical impact on the resident cells
(Figure 1).
4.1. Cell-Cell Interaction. Cell-cell interaction is a key requir-
ement of tissue formation and repair and is almost completely
missing in single-cell therapies. This could help to explain
the lack of efficiency of such therapies, and for this reason,
the current hypothesis is that enhanced cell-cell interaction,
which is achieved in microtissues, may overcome this prob-
lem.
The general principle of spheroid generation is to estab-
lish an environment in which the intercellular forces aremore
powerful than the interaction of the cultured cells with the
matrixmolecules of the substrate [79]. Cell-cell contact seems
to play a crucial role in the homeostasis of microtissues.
Due to high cell density and the three-dimensional nature,
communication with neighboring cells is possible at all
sites of the cell membrane, and only low concentrations
of signaling molecules are necessary to regulate the tightly
packed cells [80]. Soluble molecules, such as growth factors,
hormones, and cytokines, influence the cells in an autocrine
or paracrine way. The crosstalk between cells may also occur
directly via adhesion molecules, primarily cadherins [79].
Interestingly, some cell types, such as MSCs, do not normally
express cadherins in conventional monolayer cultures but
appear to do so during spheroid formation. It has been shown
that without those adhesionmolecules, cell aggregation is not
possible, which makes them a key factor in the formation of
microtissues [81].
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Figure 1: The concept of a scaffold-free, cell-based 3D microenvironment for advanced cardiac regeneration via transcatheter-guided,
intramyocardial transplantation.
By interacting with numerous receptors, adhesion mole-
cules determine cell fate by controlling growth, proliferation,
and survival. Cell death and apoptosis are governed by
signals from neighboring cells. Importantly, omission of
these survival stimulants is fatal [79, 82]. Another indication
underlying the significance in the context of life and death
is that the degradation of cellular contacts is one of the first
signs indicating that a cell is undergoing apoptosis [79].
Intercellular networking enables the coordination of tis-
sue formation and facilitates the adaptation to new circum-
stances as an integrated system. Such synchronized opera-
tions are omnipresent during embryogenesis and also during
other naturally occurring processes, such as wound healing
and tumor invasion, which require the cells to work en bloc
[79]. This highlights even more the importance of these
features in regeneration.
Particularly in cardiac tissue, cell-cell contacts have an
unparalleled role that is well represented as intercalated
discs between cardiomyocytes. Properly built cellular con-
tacts ensure correct mechanical and electrical conduction,
which results in synchronized contractions. In microtissues,
cardiomyocytes can maintain this cell-specific capacity and
exhibit even more differentiated electrical properties than
when they are cultured as monolayers [58, 83].
Driven by intercellular communication, cells are compe-
tent to self-assemble in a certain organized order, whichmim-
ics their native, organotypic architecture [84]. The proper
construction is generally predetermined by the cell-specific
function.
Again, cardiospheres are an excellent illustration of this
concept. It has been shown that their spontaneous formation
is dependent on transforming growth factor 𝛽1 (TGF𝛽1),
which promotes epithelial-mesenchymal transition (EMT), a
morphogeneticmechanism that plays a role not only in devel-
opmental biology but also in adult tissues to induce stem cell-
like properties. Interestingly, EMT in cardiosphere formation
suggests recapitulation of the mechanisms involved in heart
morphogenesis and ischemic injury [85].
As another example, spheroids composed of endothelial
cells (ECs) form an outer layer with differentiated cells with
tight cellular contacts and an interior core with unorganized,
apoptotic cells, with the final goal of building a lumen [82].
Cocultured spheroids of mixed cell populations can also
show this self-organizing dynamic that leads to compartmen-
talization. In such aggregates, ECs, for example, always move
to the periphery to form a boundary between the enclosed
cells and the environment, similar to what they would do in
the body [2, 21].
Interestingly, because all natural tissues contain several
distinct cell types, mixed spheroids may reflect real biology
even more closely. Heterotypic cooperation is essential for
most cells to unlock their full potential [26]. Particularly
in stem cell therapy, it is important to be aware of the
different interactions and their consequences. For example,
it is important to know that ECs transplanted in vivo are
dependent on mural cells to build a stable vasculature system
connected to the host [86, 87].
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The multilevel influence of intercellular communication
on distinctive cellular features highlights the importance
of in vitro remodeling of this specific microenvironment.
Fortunately, microtissues appear to implement this essential
element efficiently.
4.2. Extracellular Matrix. Another significant feature that
makes microtissues an effective technology to mimic natural
tissues is the formation of ECM, into which the cells are
incorporated. The cells themselves produce and remodel
the components of their environment, reestablishing and
resembling the conditions in vivo [25, 76]. Thanks to their
enhanced ECM production, microtissues might therefore
increase the chances of successful cell engraftment and tissue
regeneration.
The fact that a pathologicallymodifiedECMaccompanies
numerous diseases reflects the importance of ECM home-
ostasis in tissues. A typical example is the development of
fibrosis after an MI, which aggravates disease progression
[1]. Communication and crosstalk between the cells and the
ECM in organs or microtissues are bidirectional and support
signal mediation between cells. Normal cell physiology,
including differentiation, proliferation, migration, and, most
importantly, survival, is orchestrated not only by signals from
their neighbors but also by interactions with the ECM [23,
26, 27, 76]. The ECM provides spatiotemporally coordinated
cues in forms of chemical, mechanical, and hydrodynamic
signals that have a strong impact on the cells [88]. Many cells
are anchorage dependent, and anoikis describes the process
in which apoptosis is provoked by the interruption of cell-
matrix contact [22, 89].
Engagement of particular cell receptors with molecules
of the ECM is translated and integrated into an intracellular
signal, ultimately resulting in an altered gene expression pat-
tern [27, 74]. Those signaling pathways are often the same as
the ones activated by growth factors, indicating the involve-
ment of the ECM components in the regulation of prolifera-
tive activity [90].
Furthermore, the ECM plays a key role in defining the
shape of not only the tissue arrangement but also the cell
morphology. Previous studies have shown that the cardio-
myocyte phenotype depends on extracellular proteins, such
as fibronectin or collagen. Disturbance of the well-balanced
composition may result in hypertrophy [91, 92]. Along with
the composition, the physical characteristics of different
materials surrounding the cells, such as stiffness and elastic-
ity, also determine their behavior [1].
In addition, the structural support of a rich ECM renders
tissues more robust and resistant to mechanical stress. This
is particularly important in regenerative medicine, where
cells are required to withstand the handling procedures and
transplantation to the target organ [93].
Subsequently, after implantation, the grafting of micro-
tissues depends on adequate adhesion and functional inte-
gration into the host tissue. The ECM facilitates this process
by providing the cells a temporary substrate to attach to and
enabling the essential first step during cell transplantation
[84, 94, 95].
Unlikemonolayer cultures, harvesting of themicrotissues
does not require a harsh treatment with proteolytic enzymes.
Therefore, the ECM can be conserved and pave the way for
strengthened engraftment of the microtissues compared to
their dissociated and disorganized counterparts [84, 89].
Taken together, these facts illustrate the importance of
considering a cell in its overall context because there are no
cells that are not surrounded by a matrix in natural tissue.
Microtissues offer the unique opportunity to perceive the cell
as a whole and to provide insight into all dimensions.
4.3. Angiogenesis and Hypoxia. As demonstrated, the bio-
mimetic microenvironment represents a key feature for the
overall strength of the microtissue approach. Another advan-
tage arises from the specific design of those spheroids and
relates to their angiogenic potential. Neoangiogenesis and
revascularization after ischemic tissue damage is one of the
main goals in regenerative medicine, and stem cells appear to
be an important tool to induce neovascularization [75, 89, 96,
97]. However, vascularization remains a major issue in many
tissue-engineering efforts to transfer such technologies into
clinical routine.Microtissues may offer an attractive solution.
While every tissue with a thickness greater than 100 𝜇m,
which exceeds the diffusion limitation, depends on its own
vascular network for the supply of oxygen and nutrients to
preserve cell viability, microtissues can be designed within
a rationale size range to eliminate this problem completely
[96, 98–101]. Furthermore, due to the limited mass transport
within the microtissue, a hypoxic environment is created
within the entire spheroid that is particularly present in the
core.
Consequently, this leads to a preconditioning and adap-
tion of the cells to the ischemic environment they will
be exposed to after implantation. Their intent to survive
forces them to adapt to the critical circumstances and might
therefore shorten their adjustment time after transplantation.
Several studies have revealed evidence for the improved resis-
tance to hypoxia when cells were cultured as microtissues.
The hypoxic conditions contribute to a predominance of pro-
over antiapoptotic factors and therefore make the cells more
resistant to cell death [15, 89, 102].
To become more resistant to hypoxic circumstances,
various alterations at the gene expression level are available.
Of particular relevance is the upregulation of the hypoxia-
inducible factor-1-alpha (HIF-1𝛼). It is the inductor of the
expression of numerous growth factors, such as vascular
endothelial growth factor (VEGF) and insulin-like growth
factor-1 (IGF-1), which both have strong angiogenic poten-
tial [89, 99, 102, 103]. Different studies have verified a
size-dependent secretion in microtissues that also indicates
hypoxia as a powerful driving force of these factors [58,
99, 102]. The subsequent amplification of these substances
profoundly stimulates the development of vessels in vitro and
in vivo [17, 76, 89, 102–109].
However, the supply of these factors unaccompanied by
any cells has been proven to be insufficient to establish a stable
vascular network [101].
This makes microtissues the ideal candidates to deliver
not only stem cells but also the necessary angiogenic factors
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to stimulate neovascularization and subsequent coupling to
the host system [18, 103, 104, 110].
4.4. Niche-Like Conditions. The previous chapters have already
demonstrated the multifaceted impact of the microenviron-
ment on cellular physiology. An appropriate environment is
often a precondition for cells to maintain their phenotype,
including their differentiated gene expression levels. Every
cell expresses only a certain repertoire of the whole genome
that is specified for the distinct cell type. This individual
spectrum of expressed genes can be further altered according
to external circumstances, showing that the surrounding of a
cell has a profound influence on its functionality [90]. In this
regard, microtissues might reveal unprecedented conditions
that are beneficial for the stem and progenitor cells used for
clinical therapies.
It is widely acknowledged that cells can have dramatically
changed expression patterns depending onwhether theywere
cultured three-dimensionally or as monolayers [26, 74]. It
has been proven that several cell types are prone to lose
their most important characteristics when cultured in a two-
dimensional manner. Examples underlying the fundamental
impact of the environment on functionality include ECs los-
ing their tight junctions and therefore their barrier function
or hepatocytes, which become less viable and drop their key
functions, such as detoxification [25, 26, 82, 111–114].
Interestingly, cardiac progenitors also show different
gene expression profiles depending on their culture mode.
Although progenitor populations are isolated with different
isolation techniques and cultured with different medium
conditions (c-Kit+, Sca-1+ cells, and CDCs), they display
very similar gene expression patterns when cultured in
monolayers. By contrast, 3D-cultured cardiospheres have
been shown to upregulate the expression of genes encoded
for signaling molecules, such as BMP-2, HGF, LIF, PTGS-2,
VEGFA, and PDGFRB, which direct cardiac development,
angiogenesis, and cardioprotection during heart failure [115].
In addition, in the setting of stem cells, themicroenviron-
ment seems to determine the functional capacity of the cells,
in this case their stemness. Often called a stem cell “niche”,
the surrounding of the cells is responsible formaintaining the
majority of the cells in a quiescent state. It is the niche role
to react to a perturbation, such as tissue injury. Active signal
transmission to the progenitors might enable an organism to
reestablish the destroyed balance by inducing proliferation
and differentiation. Therefore, the stem cell niche, with its
panoply of structural signals and different growth factors,
has a profound impact on their plasticity, particularly the
maintenance of multilineage differentiation, expansion, and
migration [9, 22, 27, 28, 48, 50].
Stem cells can lose their pluripotency and self-renewal
capacity when cultured as monolayers [94]. Several studies
onMSCs have confirmed themaintenance of their expansion
efficiency, the upregulation of pluripotency markers, and
an enhanced differentiation capability along mesenchymal
lineages, as well as their transdifferentiation into neuron- and
hepatocyte-like cells when cultured as aggregates [81, 93, 94,
116]. One reason for this improved multipotency of MSCs
might be epigenetic changes in pluripotency-associated genes
induced by 3D cultivation [117].
In addition to cell-cell and cell-matrix contact, another
contributor to the promotion of pluripotency present in
microtissues is the aforementioned hypoxia [118, 119].
Another advantage of stem cells is their potential to
migrate to injured tissues where they are needed. Stem cells
in microtissues appear to have altered homing properties,
leading to improved migration qualities [120, 121].
MSCs can also be stimulated to produce many different
protective molecules, including anti-inflammatory factors.
The given conditions in spheroid cultures seem to cause intra-
cellular stress, leading to aMSC-induced self-activation of an
anti-inflammatory response. Interestingly, higher amounts of
these factors are already available in the microtissues before
they are implanted into the inflammatory milieu [80, 122].
It is challenging to identify the individual cues and forces
prevalent in this specialized niche, all of which contribute
to the stemness of cells in a synchronized fashion. It would
be an extremely arduous task to provide all these factors
individually in an attempt to artificially mimic this niche
[88, 113].
Therefore, the specific microenvironment of microtissues
may better resemble the natural stem cell niche and may
optimize the therapeutic efficiency of MSCs, which is closely
related to conservation of their stemness [22, 81].
4.5. In Vitro Model for Cardiac Regeneration. To obtain a
better insight into the basic biological processes, it is crucial
to take into account all dimensions of nature that are barely
present in the current two-dimensional approaches. There-
fore, the biomimetic microenvironment of microtissues may
represent a more relevant tool to study in vitro basic biology
and physiology including cell interaction, adhesion, migra-
tion, and tissue formation [21, 25, 74]. These preliminary
studies are necessary before implementation of a regenerative
therapy in vivo, whether into animals or humans.
In embryology and developmental biology, three-dimen-
sional spheroid models are already being used to identify the
environmental cues that are crucial for morphogenesis. It has
become evident that both preprogrammed gene expression
patterns and extracellular impulses, such as mechanical
forces, are responsible for correctly guiding the development
[74].
Inspired by the use of microtissues in drug screening and
tumor research, translational researchers are also interested
in using these tools to study regeneration. For example, in
cardiac regenerative medicine, the concept of microtissues
may represent a suitable platform to examine cardiomyocytes
in a controllable 3D milieu. It could efficiently provide
insight into their pharmacological, electrophysiological, and
intercellular behavior [123–128]. Microtissues with long-term
contractility aswell as the stable expression of cardiac-specific
surface markers can be generated through the self-assembly
of isolated cardiomyocytes [58, 124, 129].The assembly of cells
from heart biopsies produces a natural composition of heart
tissue.These tissues have been used to determine principles of
cellular interactions between cardiomyocytes and fibroblasts,
which are significant in pathophysiology [129]. In addition,
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this spheroid assay could be used to find the necessary
factors for directing the differentiation of stem cells into
cardiomyocyte phenotypes [124]. Microtissues also represent
an interesting in vitro model for graft-host interactions in
cardiovascular regenerative medicine because engraftment
and integration of transplanted cells are based on the same
mechanisms behind aggregation [91].
5. Microtissues in Regenerative Medicine
5.1. Safety. A cell-based therapy has to be effective and safe.
Some major concerns of stem cell-based microtissue treat-
ments are severe immune reactions [108, 130], tumorigenicity
[131, 132], embolism [42, 130, 132, 133], and the assumption
that multicellular microtissues may cause microvascular
obstruction that results in myocardial damage [130]. This
chapterwill focus on these safety concerns that are specifically
attributed to microtissues in the preclinical and clinical
setting of cardiac regeneration.
Autologous cell sources are of particular interest because
immunologic rejection is avoided [130]. Nevertheless, there
are functional, technical, and logistical drawbacks to using
autologous cells, such as patient-specific variability, time-
consuming cell expansion, and delayed availability. As an
alternative, immediately applicable, well-characterized, and
standardized allogeneic cell sources from healthy donors
might be advantageous. However, the literature to date is
contradictory regarding their in vivo immunogenicity.On the
one hand, it has been shown that allogeneic immunoprivi-
leged stem cells, such as MSCs, become immunogenic and
change their secretory profile after differentiation [134, 135].
On the other hand, several clinical trials addressing car-
diac regeneration have demonstrated that clinically relevant
allogeneic cell types, such as MSCs, CDCs, and embryonic
stem cell-derived cardiac progenitors, can be applied safely
without provoking immunological rejection [13, 136, 137].
This might be explained by the fact that these cells are short
lived and/or do not differentiate into immunogenic cells, such
as cardiomyocytes. Moreover, they exert their regenerative
potential primarily by paracrine effects. While the aforemen-
tioned studies address stem cell therapy with single-cell sus-
pensions, the question of allogenicitymight be different in the
three-dimensional microtissue environment, which changes
cell behavior and gene expression [21, 138]. Tseliou et al.
addressed this question by characterizing the immunologic
profile of allogeneic, cardiac-derivedmicrotissues by evaluat-
ing their safety and efficacy in repairing ischemic heart tissue.
Cardiospheres express a low immunogenic profile in vitro
and inhibit the proliferation of alloreactive T cells. Syngeneic
and allogeneic cardiospheres attenuate the inflammatory
response that is histologically observed in the peri-infarct
region. Furthermore, an increase inmyocardial viability in an
infarcted rat heart, as well as decreased scar size, improved
cardiac function, and attenuated adverse remodeling, could
be observed without deleterious immunological sequelae.
The large functional andmorphological benefits of allogeneic
cardiospheres in acute MI highlight the therapeutic potential
of these cardiac microtissues. Their hypoimmunogenic phe-
notype enables cardiospheres to evade alloimmune reactions
and to modify the proinflammatory milieu created after
MI [108]. While the question of immunogenicity has been
addressed in stem cell therapy, it appears to be complex and
controversial, and further investigation for both the 2D and
3D cell delivery formats is needed.
In addition to immunogenicity, tumorigenicity also rep-
resents a safety issue that has to be addressed.A 3Dcell system
using poly-L-ornithine seeded with putative cardiac stem
cells isolated from the adult canine heart showed that trans-
planted cardiospheres survived transplantation conditions
and did not form tumors even at 3 weeks posttransplantation.
The cardiospheres displayed characteristics of undifferenti-
ated cells and differentiating cardiomyocytes and/or vascular
cells. Together with their ability to undergo differentiation
into various cardiac cell types, as well as their relative
resistance to oxidative stress, the lack of tumor induction in
vivo supports cardiospheres as a suitable delivery system of
stem cells for tissue regeneration [131].
Another concern that has been raised regarding the safety
of microtissues is embolism. Preclinical studies in rodents
and pigs indicate that the self-assembling microtissues may
be more effective than dispersed CDCs. However, the more
desirable intracoronary route has been assumed to be unsafe
for cardiosphere delivery [130]. Cardiospheres are large (30–
150 𝜇m), and given that capillaries have diameters of only
8 𝜇m, intracoronary delivery of cardiospheres was assumed
to be implausible given the likelihood of coronary microem-
bolization [42, 130, 132, 133]. A dose-ranging study in minip-
igs using optimized cardiosphere size was performed to
assess the feasibility and safety of intracoronary cardiosphere
infusion [130] as well as direct injection through thoraco-
tomy [132]. There were no deaths (sudden or otherwise)
in either group after the immediate periprocedural period.
Moreover, postmortem examinations with gross analysis as
well as histology of the heart, brain, kidney, lung, liver, and
spleen detected no tumors 8 weeks after intramyocardial
injection of CDCs or cardiospheres [132]. Therefore, intra-
coronary delivery of cardiospheres appears to be safe and also
remarkably effective in decreasing scarring, arresting adverse
remodeling, increasingmyocardial perfusion, and improving
hemodynamic status after MI [130].
While efficacy is highly desirable in stem cell therapy, it is
first critical to thoroughly address safety issues. Microtissues
have shown promising safety profiles thus far, which will
hopefully be confirmed in future studies.
5.2. Spheroids as Stem Cell Vehicles. Regenerative medicine
has been repeatedly suggested as a promising, next-
generation approach to treat diseases because it tries to not
only treat the symptoms but also address the root of the
problem by replacing the lost cells and regenerating the
diseased tissue. In this regard, stem cell-based therapies
have raised substantial hope for curing degenerative diseases
and damaged tissue. Preclinical studies have shown that
such therapies can functionally improve diseased tissue after
pathologic events, such as MI [139], osteoporotic bone loss
[140], or cartilage lesions [141].
Microtissues, as an alternative cell format to single-
cell therapies, have been launched as a powerful delivery
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tool to serve as stem cell vehicles. Furthermore, preclinical
studies from numerous fields of regenerative medicine have
demonstrated superior qualities to their single-cell analogs.
Hepatocytes cultured as microtissues could avoid the loss of
their specific gene expression and produce more detoxifying
proteins when implanted into the liver. Chondrospheres
could be successfully integrated into damaged cartilage with-
out losing their differentiation capacity, which would occur
if they were cultured as monolayers. Other examples are 3D
aggregates of neurons, which are being tested as an alternative
therapy for Parkinson’s disease, or the transplantation of
insulin-producing islets to treat diabetesmellitus [3, 141–145].
5.3. Cardiovascular Therapy. The following subchapter will
discuss in more detail the potential of microtissues in the
setting of cardiovascular regenerative medicine. Although it
has been shown that the heart holds a certain capacity of self-
renewal, it is evident that this regeneration potential cannot
keep pacewith the number of cells needed after cardiac injury,
such asMI [6, 75, 146].Therefore, not only a high cell number
is essential to be delivered but also the cells need to attach to
the host tissue, integrate, and survive to finally ensure long-
term engraftment and efficacy [3].
In addition to the identification of the ideal cell source,
it is crucial to optimize the delivery approach, including
the route of delivery and, particularly, the cell format [3,
10]. Single-cell delivery has been the standard approach for
cell-based therapies, and many different stem cell sources
and delivery methods have been evaluated with promising
outcomes in preclinical trials. However, despite success-
ful advancement into the clinical setting, most of these
approaches have failed to confirm the preclinical results and
did not reveal substantial clinical evidence [3, 5, 10, 147]. One
of the main obstacles for a successful translation into the
clinical setting of cell-based therapies seems to be the poor
engraftment and survival of the cells. The majority of the
cells are washed out after transplantation, mainly because of
venous drainage and contractions of the heart [17, 147–150].
To overcome these limitations, other cell delivery formats,
such as self-assembled microtissues, have been proposed
and investigated in several preclinical studies that have
indicated several advantages when compared to their single-
cell counterparts [121].
Microtissues provide the cells with an artificial network
that behaves like the natural biology. The cells can reside
within a microenvironment that contains vital cellular inter-
actions and contact with ECM components. Therefore, they
could serve as stem cell vehicles and ensure the attachment of
the cells, which is the first prerequisite for long-term survival.
Owing to their size, 3D cell aggregates are more likely to
engraft within and subsequently adhere to the interstices of
a tissue. This is attributed to their inherent ECM, which
provides a temporary matrix to attach to [84, 107]. Various
studies have demonstrated the greater (up to 14-fold) engraft-
ment potential of different cell spheroids compared to single-
cell suspensions when they are implanted intramuscularly or
intramyocardially into rodents [17, 84, 94, 103, 107, 133]. Using
microtissues as vehicles for the cells appears to be a promising
alternative to guarantee an enhanced degree of mandatory
engraftment, rendering the use of scaffolds, genetic modifi-
cations, or a supply of growth factors unnecessary [3].
After attaching to the host tissue, the next crucial step
involves the appropriate integration and simultaneous inhibi-
tion of apoptosis despite the new, hostile microenvironment.
Unprotected single cells are predetermined to undergo
apoptosis when entering the hypoxic and inflammatory
milieu of an ischemic tissue [89, 149–151]. Several studies
have attempted to prove the enhanced survivability of cells
when cultured as microtissues and showed more abundant
and fewer apoptotic transplanted cells in the host tissue [17,
107, 121, 152].
Another environmental factor that contributes to cell
death after implantation is the inflammatory milieu [102].
Provoked by the enrichment of reactive oxygen species and
other toxins in the ischemic context, the tissue is infiltrated by
activated immune cells, which can even deteriorate the situa-
tion [153]. It has been proven that aggregation of stem cells
could also enhance their anti-inflammatory characteristics,
which could help them counteract this hostile environment
[80].
A recent study of a preclinical porcine model showed
that the intramyocardial injection of microtissues composed
of MSCs caused increased retention and integration rates as
well as improved survival compared to the corresponding
single-cell suspensions [5, 10].The study was carried out with
a three-dimensional NOGA electromechanical mapping-
guided approach [10]. The same transcatheter-based delivery
of microtissues was also used in a model of ischemic car-
diomyopathy, showing thatmicrotissues could also be helpful
in a chronic setting. This situation is even more difficult
given that the acute homing signals are already absent and
that the negative remodeling process has already taken place
[133, 154]. In a study by Yee and colleagues, the delivered cells
were not MSCs but cardiac progenitor cells (CPCs), which
are an alternative cell source for cardiac repair. In addition to
their ability to differentiate into vascular cells and contribute
to angiogenesis through paracrine effects, they also hold the
capacity to differentiate into cardiomyocytes and therefore
contribute to direct regeneration of the heart [41, 42, 152,
155–157]. Cardiospheres are generated from biopsy material
expanded in vitro and consist of different cell types, including
progenitor cells surrounded by supporting cells and the ECM
[152]. This composition mimics the natural niche in which
the cardiac progenitors reside that is favorable for the survival
and stemness of the cells [15, 121, 152, 158–160].This particular
niche seems to be essential for the stem cells tomaintain their
viability and differentiation potential [88]. Indeed, it has been
demonstrated that spheroid culture led to an upregulation
of stem cell-relevant factors, and the fraction of the c-Kit+
cells (which are thought to be the progenitors of the heart)
increased over time [152, 160].
Another method for the formation of cardiospheres
involves human pluripotent stem cells (hPSCs) and can
avoid the need for biopsy. However, the usual techniques
for enriching the fraction of cardiomyocytes from hPSCs are
very laborious, dependent on antibodies or dyes, and still
inefficient for generating the desired purity. This approach
relies on the strong tendency of the cardiomyocytes to
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aggregate. Because the other cells in the hPSCs mixture do
not share this property, the result is an enrichment of the
surviving cardiomyocytes [161].
Several preclinical trials with cardiospheres in the setting
of MI have revealed evidence for the efficacy of this cell
type cultured asmicrotissues. Promotion of angiogenesis and
attenuation of the inflammatory conditions as well as the
increased engraftment resulted in improved cardiac function
and the prevention of remodeling [108, 152].
Furthermore, it has been shown that the microtissue
technique is applicable to different stem cell sources relevant
to cardiac stem cell therapy [16].
Regenerative medicine of ischemic diseases aims at the
initiation of neovascularization. It is evident that cardiac
microtissues can only survive and function in the long run
when their vascularization is ensured. Many cells in the
damaged tissue are in a hibernating state due to ischemia and
could be saved if early revascularization is supplied [97].
Stem cells, especially MSCs, reconstruct a vascular net-
work through two mechanisms. On the one hand, they can
differentiate into endothelial and vascular smooth muscle
cells, which directly contribute to the formation of new vessel.
On the other hand, they can facilitate angiogenesis through
paracrine mechanisms, recruiting endogenous ECs to induce
vascularization [109, 162–165].
Therefore, the efficacy of MSCs is mainly attributed to
their paracrine effects. To address neovascularization during
cell therapy, microtissues have immense potential because
they can be modulated in composition and therefore in their
functionality. They are able to secrete higher amounts of
proangiogenic factors that they can also keep within the
spheroids, preventing dilution within the growth media [58,
76, 89, 93, 102, 103, 108, 109, 121]. Microtissues made of
rat cardiomyocytes have been shown to produce angiogenic
factors in vitro [58] and are able to connect to the vascular
system of chicken embryos after transplantation [18].
The beneficial effects on angiogenesis have been proven
both in vitro and in vivo. Transplantation of different types
of microtissues can lead to enhanced neovascularization and
thus limb salvation in mice hind limb ischemia [89, 102].
Moreover, these cells have been proven to be beneficial in
rodent MI models, where the induced vascular network sup-
ported the restoration of cardiac function and the attenuation
of cardiac remodeling [17, 103, 107].
Another promising approach is the aggregation of mixed
cell bodies. This method could foster further advances in
the field of angiogenesis. By enveloping MSCs with a shell
of ECs, microvessels can already be formed on the level of
the 3D spheroid. Because ECs need contact with perivascular
cells to become responsive to growth factors, they rely on a
teammate.MSCs can fulfill this requirement by stabilizing the
formed vessels and simultaneously providing the necessary
growth factors. The efficiency of this innovative core-shell
technique has also been observed in several in vivo models
[76, 109].
Microtissues seem to have the potential to enrich and
improve cell-based therapies. This has already been shown
in preclinical small and large animal studies, as described
above. Initial cell-based clinical trials for cardiac regeneration
were performed with single cells and outlined the safety
and feasibility, although they were not convincing regarding
therapeutic efficiency [8]. One major reason for this is the
poor engraftment of the injected cells, and therefore, next-
generation cell therapies with improved 3D cell formats,
such as microtissues, are needed [166]. However, to date, no
clinical data investigating the impact ofmicrotissues on tissue
regeneration are available. However, given their diversity,
simplicity, and reproducibility, microtissues as biomimetic
vehicles appear to be a promising tool for further enhancing
current stem cell therapy strategies.
5.4. Building Blocks: From Micro to Macro. Taking into
account all the beneficial features of microtissues in stem
cell therapy, it is clear that they might have the potential to
be taken to the next level, which would be to use them to
generate macrotissues. In tissue engineering, it is desirable to
artificially design a perfect tissue or even duplicate an organ
in vitro that could be successfully integrated into a host.
Given their capability to fuse with one another, 3D
spheroids could exploit their full potential in larger tissue
constructs by shifting the scale from micrometer to millime-
ter or even larger [93, 167]. In the complex field of tissue
engineering, it is always desirable to mimic biological micro-
environments. Natural tissues are generally built modularly
by assembling organs from hierarchically organized units.
The lobules of the liver, alveoli of the lungs, and nephrons
of the kidneys are all excellent examples of this construction
concept [25, 100].
Current methods of designing thicker tissues mainly
involve scaffolds, which are very beneficial for tissues that
needmechanical guidance to force them into a specific geom-
etry, such as heart valves or blood vessels. More dynamic
organs, such as the myocardium, might be impaired by the
mostly rigid, shape-supporting materials [3, 58].
Scaffolds seeded with different cells bring the artificial
tissue into the desired form. However, they are limited in
the physiological integration of themultifaceted signals [167].
Because they are biomimetic and provide the appropriate
setting to ensure phenotypes that are reminiscent of the cells
in vivo, microtissues could serve as attractive building blocks
and eliminate the need for scaffolds [77].
There is one major obstacle to engineering larger tissue
implants that needs to be solved before a strategy can be
successfully transferred to clinical practice. Cells within the
artificial tissue construct must remain viable in vitro as well
as in vivo after transplantation [1]. However, as diffusion is
limited to a distance of 150–200𝜇m, a blood vessel supply
represents a prerequisite in tissues exceeding this thickness
[96].
An implant can be equipped with purified angiogenic
factors to promote the rapid recruitment of host cells to
vascularize the tissue in situ, but controlling the release of
these instable molecules remains challenging. In addition,
it has been proven that chemical reagents alone are not
sufficient to create a stable vasculature network [101, 167, 168].
Therefore, another strategy is to build the vascular net-
work in vitro by colonizing the organoids with cells com-
petent to establish inherent blood vessels. However, ECs are
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prone to undergo apoptosis when seeded into somematrices,
such as collagen or matrigel [169]. In contrast, seeding ECs
into the context of microtissues would be feasible because
these cells survive in aggregates. By amplifying the angiogenic
anddifferentiation potential of these cells, 3D spheroids could
be the starting point for developing capillaries. Those could
then be easily incorporated into the tissue and ensure that the
required blood supply is available [96, 99]. Angiogenesis, like
all processes in the body, takes place in all three dimensions
and requires an environment that reflects this intricacy. In
addition, microtissues also provide the mandatory ECM
elements and a high cellular density to make spheroids the
perfect vascularization units [25].
The efficiency of this strategywas demonstrated in a study
where MSC spheroids were seeded on a scaffold, enabling
the formation of a vasculature network connected to the host
blood circulation systemwhen implanted into dorsal skinfold
chambers of mice [96].
When coated with ECs, microtissues could even improve
vascularization. Thanks to the high degree of cellular self-
organization in 3D, ECs already induce the formation of
microvascular structures within the spheroids and are dis-
posed to anastomose to the host network [25, 99].
More importantly, cardiomyocyte spheroids can be
coated with either ECs or MSCs to create new blood vessels
within the aggregates without the addition of any growth
factor [97].
The feasibility of creating microhearts was demonstrated
by Kelm et al., who were able to generate beating heart aggre-
gates out of cardiomyocytes. In addition to the maintenance
of a mature phenotype, the aggregates were also electrically
coupled and showed the capacity to synchronize their beating
frequency when various microtissues were planted together.
Intermicrotissue forces that generate electrical continuity are
essential for building larger tissues as well as for integration
into the hosting heart without causing arrhythmias [58].
In addition, tissue-engineered blood vessels can be cre-
ated with specific microtissues. This was shown in a fully
autologous approach that was completely free of any foreign
material. In an assembly device, the microtissue units, which
were composed of fibroblasts and ECs, were manipulated to
assemble into a tubular shape [170].
In addition to the need for an efficient vasculature,
there are other issues in designing larger tissues in vitro
that demand an alternative to scaffold-based approaches.
Seeding scaffolds with cells rarely results in a sufficient and
homogenous cell density, and the positioning of the cells
remains difficult. However, the tissue construct needs to have
a specific, organ-like shape, which is very challenging to
accomplish without a scaffold [171].
3D spheroids may overcome these hurdles because their
shape can be adapted according to their desired application,
they naturally provide ECM, and they have a great potential
for vascularization. All of these favorable characteristics
qualify microtissues as appropriate tissue units [3].
However, it is necessary to precisely control the micro-
tissue position in the complete system to obtain the optimal
outcome. The use of bioprinting to achieve this control is
raising significant hope in the field of tissue engineering.
Microtissues are placed robotically using a tool similar
to an inkjet printer. The positioning of the spheroids in
all dimensions is controlled by a computer and results in
complex tissue constructs or even whole organs composed of
different cell types embedded in an ECMmaterial [21, 93].
High precision, scalability, and the infinite combination
possibility using different spheroids all suggest that microtis-
sues could be the new pixels in tissue engineering [171].
6. Outlook
Regenerativemedicine represents a growing field for a variety
of diseases. Regenerative strategies are needed for cardio-
vascular disease in particular because the heart has only
a limited capability of self-regeneration. Although numer-
ous experimental and preclinical studies have demonstrated
promising data, the outcomes of the initial clinical trials
appear to be rather poor and indicate a lack of translation.
Several key issues remain to be elucidated, including the
ideal cell source and optimal cell format. In particular, the
poor cell engraftment rate after transplantation of single-
cell suspensions remains a major obstacle and needs to be
addressed to enhance the therapeutic efficacy of cell-based
concepts.
The unique tissue-like microenvironment that can be
generated in microtissues may represent an interesting solu-
tion to increase cellular retention after delivery and sub-
sequently enhance efficacy. In particular, the cellular envi-
ronmental interactions mediated by neighboring cells and
the secreted ECM may support physiological cell behavior
and increase cell survival after transplantation because these
environmental cues have crucial signaling properties. In
addition, the hypoxic and inflammatory preconditioning
within microtissues may further enhance homing, adaption,
and, importantly, survival in the targeted injured tissue.These
promising prerequisites of microtissues may pave the way for
cell-based therapies with optimized entrapment, long-term
retention, and improved clinical outcomes. In addition, the
microenvironment withinmicrotissues can be easily adjusted
to the requirements of specific tissues by using and combining
different cell sources. The resulting individual and unique
microenvironments may have advantages for regenerative
therapies for many diseases. Specifically, the combination
of cell types with synergistic regenerative and paracrine
effects might advance current strategies. The combination of
MSCs and CPCs to treat chronic ischemic cardiomyopathy
improves cardiac functionmore significantly than does treat-
ment with MSCs alone, as shown in a recent preclinical trial
[172]. These results provide evidence that next-generation
cardiac cell therapies should include different cell types, and
we envision that this effect could be enhanced when cells
are delivered as microtissues, which would enable the close
interplay between cell types. Depending on the cell source,
the use of microtissues in regenerative medicine is suitable
for both autologous personalized and allogeneic off-the-shelf
therapies. Importantly,microtissues represent an ideal hybrid
solution by combining the therapeutic advantages of both
engineered tissues and single cells. On the one hand, they
provide an advanced 3D cellular microenvironment, and on
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the other hand, they are still applicable via catheter-based
approaches because of their size. As demonstrated by our
group in a preclinical trial in the setting of MI, the spatially
precise, catheter-based injection of engineered microtissues
into ischemic cardiac target tissues is already feasible and safe
[10]. After proving the feasibility and safety of this approach,
the next step will be the investigation of its in vivo efficacy,
including a head-to-head comparison with single cells. To
translate this promising cell format from bench to bedside,
it is important to perform proof-of-concept clinical studies.
The newly established automated platforms for the standard-
ized production and processing of microtissues may be an
important tool to facilitate a GMP-compliant manufacturing
process of the cell product. One of the remaining challenges
to be addressed is the successful biobanking of microtissues
of different cell types, which would reduce logistical issues,
save money, and provide an immediately available off-the-
shelf cell product. Next, to make cell therapy predictable and
to study its fate in vivo, it is important to track the cell product
after implantation. The visualization of injected single cells
remains a challenging task that could be circumvented by the
use of therapeuticmicrotissues, which consist of a large group
of aggregated cells that can be easily labeled and detected.Our
group has shown that microtissues composed of cells labeled
withmicron-sized paramagnetic iron oxide (MPIO) particles
could be tracked in vivo using serial magnetic resonance
imaging (MRI) after intramyocardial transplantation into a
porcine heart [10]. We envision that the improvement of
cardiac cell therapies could be achieved thanks to the tracking
possibility of microtissues in vivo. This would allow their
mechanism of action, their efficacy after injection, and their
effect on cardiac regeneration to be studied.
In addition to the huge potential of microtissues for
tissue regeneration, they may also serve as powerful building
blocks for the generation of larger tissues or even whole
organs, which is still an important need because of the general
organ shortage in different medical fields. Microtissues also
represent an interesting format to advance basic research.
Their unique microenvironment, mimicking physiological
cell behavior, can be utilized and modified to simulate and
investigate diseases. While microtissues are an established
model in tumor biology, they could play a significant role in
the evaluation of various diseases at the interface between
in vivo and in vitro. Finally, the combination of different
microtissue-based microenvironments resembling different
organs with a microfluidic system may provide the oppor-
tunity to study the physiological interplay between organs
in complex multiorgan models in vitro [173]. Such a system
could also be advantageous for drug testing in a setting that
mimics the whole body [174].
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